Panel Discussion: Injectables in focus – Therapeutic areas driving market growth

Moderator:
• Dr Mallinath S Harwalkar, VP – R&D, Hetero

Panelists in this video:
• Mr Raja Sekhar Reddy Vanga, VP – Global Regulatory Affairs, Biocon Biologics
• Mr Santosh Katti, VP – Drug Product Operations, Biocon Biologics
• Dr Srikanth Reddy Sokkula, Head – Regulatory Affairs, Jodas Expoim
• Mr Pavankumar R Gudi, Manager, Serum Institute of India

Key Highlights:
[1] Chronic conditions such as autoimmune diseases, diabetes, cancer, and pain are the primary drivers of injectable market growth

[2] Prefilled syringes, auto-injectors, and smart delivery systems are driving patient adherence, ease of use and market differentiation

[3] Biologics and biosimilars are accelerating the growth of injectables by expanding patient access, and driving innovation in drug delivery formats

[4] The supply chain for injectables must be robust, connected, agile, and resilient to ensure seamless delivery and accessibility right up to the last mile of patient care

[5] Long-acting injectables boost market growth by improving adherence, reducing dosing frequency, and enhancing outcomes in chronic care